Abstract

PurposePituitary metastases (PM) are uncommon findings and are mainly derived from breast and lung cancers. No extensive review of PM from neuroendocrine neoplasms (NENs) is on record. Here we describe a clinical case of PM from pancreatic NEN and review the clinical features of PM from NENs reported in the literature.MethodsA case of PM from a pancreatic NEN followed at our institution is described. We also reviewed the 43 cases of PM from NENs reported in the literature.ResultsA 59-year old female patient, previously submitted to duodeno-cephalo-pancreasectomy for a well-differentiated pancreatic NEN, with known hepatic metastases, underwent a 68 Ga-DOTATOC PET/CT that revealed an uptake in the pituitary gland. A subsequent MRI displayed a pituitary lesion, with suprasellar extension. After a hormonal and genetic diagnostic workup that excluded the diagnosis of MEN 1, the worsening of headache and visual impairment and the growth of the lesion lead to its surgical removal. A pituitary localization of the pancreatic NEN was identified. Regarding the published cases of PM from NENs, the most common tumour type was small cell lung cancer (SCLC), accounting for nearly half of the cases, followed by bronchial and pancreatic well differentiated NENs. The most frequent symptom was a variable degree of visual impairment, while headache was reported in half of the cases. Partial or total anterior hypopituitarism was present in approximately three quarters of the cases, while diabetes insipidus was less common. The most frequent treatment for PM was surgical resection, followed by radiotherapy and chemotherapy. The clinical outcome was in line with previous reports of PM from solid tumours, with a median survival of 14 months. Surgery of PM was associated with prolonged survival.ConclusionsPM from NENs have clinical features similar to metastases derived from other solid tumours, albeit the involvement of the anterior pituitary seems more frequent; a thorough pituitary hormonal evaluation is mandatory, after focused radiological studies, particularly if a surgical approach is considered. The optimal management of PM remains disputed and seems mainly driven by the aggressiveness of the primary tumour and the presence of symptoms. In well-differentiated NENs, particularly in the case of symptomatic PM, surgical removal may be a reasonable approach.

Highlights

  • Pituitary metastases (PM) are uncommon findings and their reported incidence is variable

  • Pituitary (2021) 24:828–837 we reported the case of a PM from a pancreatic neuroendocrine neoplasms (NENs) managed at our centre and we reviewed the published literature regarding PM from NENs, describing their main clinical, diagnostic and therapeutic features

  • We presented a rare case of PM from a pancreatic neuroendocrine tumour (NET), which gives us the opportunity to speculate on the tools for distinguishing this lesion from a pituitary adenoma and to revise the literature on metastatic localizations of NENs in the pituitary gland

Read more

Summary

Introduction

Pituitary metastases (PM) are uncommon findings and their reported incidence is variable. The pathology report was consistent with a G1 well-differentiated pancreatic neuroendocrine tumour (NET) (Ki-67 index: 4%) with metastasis in 1 out of 32 excised lymph nodes. The patient underwent restaging scans with both 68 Ga- and 18F-FDG PET/CT, which showed no uptake in the pituitary region and stability of the known liver and lymph node metastases. The patient is currently in good clinical conditions and pituitary deficiencies are well controlled by replacement therapy two years after pituitary surgery and 13 years after pancreatic NET resection. Her therapy continues with monthly octreotide with good tolerance

Literature review
Findings
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call